Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Muriel Liberto ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
With Its Vanda Pharma And Berkheimer Memos, USPTO Provides Increased Clarity And Predictability In The Patent Eligibility Determination In A Further Boost For Stakeholders And Innovators In Personalized Medicine
In the time since the Federal Circuit issued its Vanda Pharma decision in April, Vanda Pharm. Inc. v West-Ward Pharm. Intl. Ltd. 887 F.3d 1117 (Fed. Cir. 2018) ...
United States
25 Jul 2018
2
Myriad Impact Of The Federal Circuit’s Decision In Myriad Genetics
On July 29, 2011, a split panel of the U.S. Court of Appeals for the Federal Circuit confirmed the patentability of "isolated" DNA molecules, to the relief of many in the biotechnology community. Association for Molecular Pathology v. U.S. Patent and Trademark Office (Fed. Cir. 2011).
United States
15 Aug 2011
3
Invention Assignment Following Stanford v. Roche: Implications For Technology Transfer And Government Contracts
Last week the United States Supreme Court clarified the respective invention ownership rights between federal contractors and their employee inventors under the Bayh-Dole Act (35 U.S.C. §§201(e), (c), 202(a)) ("Act") in Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc. (Sup. Ct. June 6, 2011).
United States
5 Jul 2011
Links to Result pages
 
1